



GastroPanel[®] Quick guide



Stomach health test from a blood sample

- ▶ A reliable means to differentiate healthy and non-healthy stomach
- ▶ Helps detect patients who need further examinations
- ▶ Easy to perform in association with other blood tests, a 4-hour fasting is sufficient

GastroPanel® for the first-line diagnosis of dyspepsia

A biomarker panel from a blood sample, which measures the structure and function of the stomach mucosa.

- Finds patients with a healthy stomach
- Reliably detects gastritis and *H. pylori* infection.
- Detects the often asymptomatic atrophic gastritis, with or without *H. pylori* infection.
- Gives accurate information about gastric acid output.
- Identifies subjects at increased risk of gastric cancer and peptic ulcer.
- Helps evaluate the risk of malabsorption of vitamin B12, calcium (osteoporosis), iron, magnesium, zinc and some medicines.
- With GastroPanel®, unnecessary gastroscopies will be avoided.


Risks associated with atrophic gastritis:

- Gastric cancer (corpus and/or antral atrophy)
- Malabsorption of vitamin B12, calcium, magnesium, zinc, iron and some medicines. (corpus atrophy)

Helicobacter pylori infection is an independent risk factor for both gastric cancer and peptic ulcer disease.

Over 1 000 000 patients have been tested with GastroPanel® worldwide.

Stomach specific biomarkers



The GastroPanel® test measures four biomarkers in a fasting blood sample: *Helicobacter pylori* antibodies, pepsinogen I and II, and amidated gastrin-17.

Helicobacter IgG antibodies (*H. pylori* IgG)

Helicobacter pylori only infects the gastric mucosa. The infection is usually acquired in childhood and causes inflammation (gastritis), which, if untreated, becomes chronic and life-long. The infection is common, particularly among elderly people. In many infected persons, the gastric mucosa becomes atrophic over the course of decades. Gastritis and atrophy can increase the risk of various diseases (stomach cancer, duodenal ulcer, peptic ulcer) and malabsorption of vitamin B12, iron, calcium and magnesium. An *H. pylori* IgG level exceeding 30 EIU* indicates a probable *Helicobacter* infection.

Pepsinogen I (PGI)

The serum levels of pepsinogen I reflect both the structure and function of the corpus mucosa. When the corpus becomes atrophic, pepsinogen I concentration in the blood falls below 30 µg/l.*

Pepsinogen II (PGII)

The serum concentration of pepsinogen II is another indicator of the structure and function of gastric mucosa. Output of pepsinogen II often increases when the gastric mucosa becomes inflamed (threshold 15 µg/l*). The most common cause is a *Helicobacter pylori* infection, but occasionally some other factors may cause gastritis: e.g. analgesic drugs (painkillers), strong liquor, strong spices, bile reflux.

Pepsinogen I/Pepsinogen II (PGI / PGII) ratio

The pepsinogen I/pepsinogen II ratio falls markedly (< 3)* when the gastric corpus is atrophic.

Basal Gastrin-17 (G-17b)

The concentration of gastrin-17 in the blood (fasting concentration) is an indicator of the structure and function of the stomach antrum. Biohit's monoclonal antibody specifically measures the only the level of amidated gastrin-17 peptide, which has a specific receptor only in parietal cells.


Gastrin-17 is secreted solely by the G cells in the antrum. It accelerates the secretion of hydrochloric acid in the parietal cells of the corpus. A gastrin-17 level above 7 pmol/l usually indicates an anacidic (achlorhydric) stomach (e.g. the patient is on PPI medication or has atrophy limited to the corpus). As the acidity of the stomach contents increases (pH < 2.5) the gastrin-17 level in the blood falls. The gastrin-17 level also falls in atrophic antral mucosa, as the G cells disappear. A low level* of gastrin-17b can therefore indicate either atrophy of the antral mucosa or an increased acid output in corpus.

Stimulated Gastrin-17 (G-17s)

To differentiate between antral atrophy and increased acid output, gastroscopy can be performed, or gastrin-17 response can be measured after protein stimulation. A low level of stimulated gastrin-17 (< 3 pmol/l*) can indicate atrophic gastritis in the antrum.

* GastroPanel® reference values may be subject to changes following new clinical trial data.

GastroPanel® - interpretation guide snapshot



The GastroPanel® report contains a more detailed interpretation.

GastroPanel® report by the GastroSoft® app helps interpret the results

Example report:

Patient Data

Name	Last First name
Date of birth	15.2.1953
Age	71
Eradicated	No
Use of PPI	Temporarily (pause 7 days)
Acidic symptoms	Countinously
Use of NSAIDs	No

Sample Data

Collected	12.06.2022	
Analyzed	12.06.2022	
		reference range:*
Pepsinogen I (PGI)	26,3 µg/l	30 - 160 µg/l
Pepsinogen II (PGII)	4,1 µg/l	3 - 15 µg/l
PGI/PGII	6,4	3 - 20
Gastrin-17b (G-17b)	13,8 pmol/l	1 - 7 pmol/l
<i>H. pylori</i> antibodies (HPAB)	21,5 EIU	< 30 EIU

Interpretation The results indicate atrophic gastritis (loss of gastric cells) in the corpus due to a past *Helicobacter pylori* infection, or an autoimmune disease. Gastric acid secretion is decreased. Atrophic gastritis (loss of gastric cells, "no gastric acid") is a significant risk factor for gastric cancer. Hence gastroscopy is recommended. Carcinogenic acetaldehyde forming in an achlorhydric stomach is one possible cause of gastric and oesophageal cancer. The final diagnosis can be decided after gastroscopy.

Test and create your own GastroPanel® report at www.gastropanel.com

GastroSoft® is a software application designed to assist clinicians in interpreting GastroPanel® test results with optional anamnestic information. The GastroPanel® report is intended for healthcare professionals only. Final diagnosis must be made by the physician.

* GastroPanel® reference values may be subject to changes following new clinical trial data.

Literature

1. Agréus L, Kuipers EJ, Kupcinskas L, Malfetheriner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K, Sung J. Rationale in diagnosis and screening of atrophic gastritis with stomach specific plasma biomarkers. *Scand J Gastroenterol* 2012; 47:136-147.
2. Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, Syrjänen K. Prevalence of *H. pylori* Infection and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in Kazakhstan. A Hospital based Screening Study Using a Panel of Serum Biomarkers. *Anticancer Research* 2013; 33: 4595-4602.
3. Germana B, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, Comparato G, Carloni C, Bertiato G, Battiestel B, Papa N, Aragona G, Cavestro GM, Iori V, Merli R, Bertolini S, Caruana P, Franze A. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-*Helicobacter pylori* antibodies in the management of dyspeptic patients in primary care. *Dig Liver Dis* 2005; 37:501-508.
4. Iijima K, Abe Y, Kikuchi R, Koike T, Ohara T, Sipponen P, Shimosegawa T. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. *World J Gastroenterol* 2009;15: 853-859.
5. Lombardo L, Leto R, Molinaro G, Migliardi M, Ravarino N, Rocca R, Torchio B. Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel® test. *Clin Chem Lab Med* 2010;48:1327-1332.
6. Masci E, Pellicano R, Mangiavillano B, Luigiano C, Stelitano L, Morace C, Viale E, Freschi M, Locatelli M, Ieri R, Cavallaro A, Testoni S, Testoni PA. GastroPanel® test for non-invasive diagnosis of atrophic gastritis in patients with dyspepsia. *Minerva Gastroenterol Dietol* 2014;60:79-83.
7. Sipponen P, Härkönen M. Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? *Scand J Gastroenterol* 2010; 45:133-138.
8. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M, Agréus L. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. *Scand J Gastroenterol* 2008; 43: 1448-1455.
9. Telaranta-Keerie A, Kara R, Paloheimo L, Härkönen M, Sipponen P. Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4256 volunteers without specific complaints. *Scand J Gastroenterol* 2010; 45:1036-1041.
10. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, Koskenpato J, Sotka M, Turunen M, Sandström R, Ristikankare M, Jussila A, Sipponen P. Non-Endoscopic Diagnosis of Atrophic Gastritis with a Blood Test. Correlation between Gastric Histology and Serum Levels of Gastrin-17 and Pepsinogen I. A Multicentre Study. *Eur J Gastroenterol Hepatol* 2003; 15: 885-891.
11. Syrjänen K. A Panel of Serum Biomarkers (GastroPanel®) in Non-invasive Diagnosis of Atrophic Gastritis. Systematic Review and Meta-analysis. *Anticancer Res.* 2016 Oct;36(10):5133-5144.

Biohit Oyj, Laippatie 1, 00880, Helsinki, Finland

Tel. +358 9 773 861 info@biohit.fi

www.gastropanel.fi

Find subsidiaries and distributors at biohithealthcare.com

BIOHIT
Innovating for Health